FDA OKs New GERD Drug Kapidex

Story Comments Share

Updated: 1/17/2013 6:20 pm Published: 11/27/2012 8:34 pm

Feb. 6, 2009 -- The FDA has approved Kapidex delayed-release capsules as a once-daily treatment for gastroesophageal reflux disease (GERD) and for erosive esophagitis, which is GERD-related damage to the esophagus.

Kapidex, which is taken orally, belongs to a class of drugs called proton pump inhibitors. It's the first proton pump inhibitor with a dual delayed release formulation, which provides two separate releases of medication, according to Takeda Pharmaceutical Company, which makes Kapidex.

In a news release, Takeda says that the FDA approved Kapidex based on global studies of about 6,000 GERD patients, some of whom had erosive esophagitis. In those studies, Kapidex trumped a placebo at treating heartburn. Among erosive esophagitis patients studied, those taking Kapidex also showed high healing rates of erosive esophagitis that were comparable to erosive esophagitis healing rates among patients taking Prevacid, another proton pump inhibitor made by Takeda.

Takeda reports that the most commonly reported adverse reactions with Kapidex included diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Story Comments Share

0 Comment(s)
Comments: Show | Hide

Here are the most recent story comments.View All

The views expressed here do not necessarily represent those of KOKI FOX23 - Tulsa

No comments yet!

The Health News section does not provide medical advice, diagnosis or treatment. See additional information.

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.